Open AccessBCLC-B hepatocellular carcinoma treatment or when should the systemic therapy be started
Author(s) -
V. Breder,
M. Pitkevich,
Э. Р. Виршке,
Л А Костякова,
И. А. Джанян,
К. К. Лактионов
Publication year - 2018
Publication title -
medicinskij sovet
Language(s) - English
Resource type - Journals
eISSN - 2658-5790
pISSN - 2079-701X
DOI - 10.21518/2079-701x-2018-10-27-32
Subject(s) - sorafenib , hepatocellular carcinoma , regorafenib , medicine , systemic therapy , refractory (planetary science) , oncology , combination therapy , overall survival , gastroenterology , biology , cancer , colorectal cancer , astrobiology , breast cancer
Choice of the optimal therapy for BCLC-B hepatocellular carcinoma (HCC) is a significant clinical problem. Transarterial chemoembolisation (TACE) is considered to be the method of choice as this approach is reported to produce a direct effect and to have a significant survival rate. However, TACE is not always applicable and produce a survival benefit due to the clinical heterogeneity of BCLC-B HCC. The article includes different approaches for BCLC-B HCC patients, TACE prediction and refractory criteria as well as the results obtained. The necessity of timely sorafenib systemic therapy in BCLC-B and in advanced HCC after TACE is discussed. Practical application of regorafenib as the second line in HCC systemic treatment is discussed.